The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
Open accessAbstract
Currently, there is no cure and no preventive vaccine for HIV/AIDS. Combination antiretroviral therapy has dramatically improved treatment, but it has to be taken for a lifetime, has major side effects and is ineffective in patients in whom the virus develops resistance. Nanotechnology is an emerging multidisciplinary field that is revolutionizing medicine in the 21st century. It has a vast potential to radically advance the treatment and prevention of HIV/AIDS. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for HIV/AIDS by advancing antiretroviral therapy, gene therapy, immunotherapy, vaccinology and microbicides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citationKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Self-citationNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Self-citationNonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Mouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
Lai, S. K., Wang, Y.-Y., & Hanes, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.002 · Cited by 1,815
Interaction of silver nanoparticles with HIV-1
Elechiguerra, J. L., Burt, J. L., Morones, J. R., Camacho-Bragado, A., Gao, X., Lara, H. H., & Yacaman, M. J. (2005) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-3-6 · Cited by 1,709
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature Reviews Immunology · doi:10.1038/nri2017 · Cited by 1,279
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO
Trombetta, E. S., & Mellman, I. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104538 · Cited by 1,173
Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform
Zhang, L., Chan, J. M., Gu, F. X., Rhee, J.-W., Wang, A. Z., Radovic-Moreno, A. F., Alexis, F., Langer, R., & Farokhzad, O. C. (2008) · ACS Nano · doi:10.1021/nn800275r · Cited by 1,038
Self-citationHumanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Friedman, S. H., DeCamp, D. L., Sijbesma, R. P., Srdanov, G., Wudl, F., & Kenyon, G. L. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00068a005 · Cited by 954
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
The immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010) · Nature Reviews Immunology · doi:10.1038/nri2674 · Cited by 871
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
HIV vaccine design and the neutralizing antibody problem
Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., & Wyatt, R. T. (2004) · Nature Immunology · doi:10.1038/ni0304-233 · Cited by 765
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
ANTIGEN-SPECIFIC MEMORY B CELL DEVELOPMENT
McHeyzer-Williams, L. J., & McHeyzer-Williams, M. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115732 · Cited by 725
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.006 · Cited by 679
siRNA Delivery into Human T Cells and Primary Cells with Carbon‐Nanotube Transporters
Liu, Z., Winters, M., Holodniy, M., & Dai, H. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604295 · Cited by 666
Wang, Y., Gao, S., Ye, W.-H., Yoon, H. S., & Yang, Y.-Y. (2006) · Nature Materials · doi:10.1038/nmat1737 · Cited by 658
The Survival Benefits of AIDS Treatment in the United States
Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., Weinstein, M. C., & Freedberg, K. A. (2006) · The Journal of Infectious Diseases · doi:10.1086/505147 · Cited by 581
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
X-Ray Structures of the Hexameric Building Block of the HIV Capsid
Pornillos, O., Ganser-Pornillos, B. K., Kelly, B. N., Hua, Y., Whitby, F. G., Stout, C. D., Sundquist, W. I., Hill, C. P., & Yeager, M. (2009) · Cell · doi:10.1016/j.cell.2009.04.063 · Cited by 523
Population-Level HIV Declines and Behavioral Risk Avoidance in Uganda
Stoneburner, R. L., & Low-Beer, D. (2004) · Science · doi:10.1126/science.1093166 · Cited by 517
The structural biology of HIV assembly
Ganser-Pornillos, B. K., Yeager, M., & Sundquist, W. I. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.02.001 · Cited by 503
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier
Tang, B. C., Dawson, M., Lai, S. K., Wang, Y.-Y., Suk, J. S., Yang, M., Zeitlin, P., Boyle, M. P., Fu, J., & Hanes, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905998106 · Cited by 453
Sun, R. W.-Y., Chen, R., Chung, N. P.-Y., Ho, C.-M., Lin, C.-L. S., & Che, C.-M. (2005) · Chemical Communications · doi:10.1039/b510984a · Cited by 440
Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Mark Saltzman, W. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 438
Nonviral gene delivery: What we know and what is next
Gao, X., Kim, K.-S., & Liu, D. (2007) · The AAPS Journal · doi:10.1208/aapsj0901009 · Cited by 431
Re-emergence of HIV after stopping therapy
Chun, T.-W., Davey, R. T., Engel, D., Lane, H. C., & Fauci, A. S. (1999) · Nature · doi:10.1038/44755 · Cited by 428
Harrigan, P. R., Hogg, R. S., Dong, W. W. Y., Yip, B., Wynhoven, B., Woodward, J., Brumme, C. J., Brumme, Z. L., Mo, T., Alexander, C. S., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/427192 · Cited by 424
Richman, D. D. (2001) · Nature · doi:10.1038/35073673 · Cited by 419
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
Palliser, D., Chowdhury, D., Wang, Q.-Y., Lee, S. J., Bronson, R. T., Knipe, D. M., & Lieberman, J. (2006) · Nature · doi:10.1038/nature04263 · Cited by 410
Challenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
Inhibition of HIV Fusion with Multivalent Gold Nanoparticles
Bowman, M.-C., Ballard, T. E., Ackerson, C. J., Feldheim, D. L., Margolis, D. M., & Melander, C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710321g · Cited by 371
Heath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5
Lederman, M. M., Veazey, R. S., Offord, R., Mosier, D. E., Dufour, J., Mefford, M., Piatak, M., Lifson, J. D., Salkowitz, J. R., Rodriguez, B., et al. (2004) · Science · doi:10.1126/science.1099288 · Cited by 352
Eguchi, A., Meade, B. R., Chang, Y.-C., Fredrickson, C. T., Willert, K., Puri, N., & Dowdy, S. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1541 · Cited by 340
McCarthy, T. D., Karellas, P., Henderson, S. A., Giannis, M., O'Keefe, D. F., Heery, G., Paull, J. R. A., Matthews, B. R., & Holan, G. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050023q · Cited by 314
The Discovery of HIV as the Cause of AIDS
Gallo, R. C., & Montagnier, L. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038194 · Cited by 303
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
RNA interference against viruses: strike and counterstrike
Haasnoot, J., Westerhout, E. M., & Berkhout, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1369 · Cited by 295
Nanoparticles for nasal vaccination
Csaba, N., Garcia-Fuentes, M., & Alonso, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.005 · Cited by 277
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
Mitsuyasu, R. T., Merigan, T. C., Carr, A., Zack, J. A., Winters, M. A., Workman, C., Bloch, M., Lalezari, J., Becker, S., Thornton, L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1932 · Cited by 261
Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates
Zhang, L., Radovic‐Moreno, A. F., Alexis, F., Gu, F. X., Basto, P. A., Bagalkot, V., Jon, S., Langer, R. S., & Farokhzad, O. C. (2007) · ChemMedChem · doi:10.1002/cmdc.200700121 · Cited by 257
Self-citationDevelopment of a macrophage-based nanoparticle platform for antiretroviral drug delivery
Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., et al. (2006) · Blood · doi:10.1182/blood-2006-03-012534 · Cited by 253
Gels as vaginal drug delivery systems
das Neves, J., & Bahia, M. F. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.012 · Cited by 252
Elamanchili, P., Diwan, M., Cao, M., & Samuel, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.12.032 · Cited by 246
Li, M.-J., Kim, J., Li, S., Zaia, J., Yee, J.-K., Anderson, J., Akkina, R., & Rossi, J. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.524 · Cited by 241
Dou, H., Grotepas, C. B., McMillan, J. M., Destache, C. J., Chaubal, M., Werling, J., Kipp, J., Rabinow, B., & Gendelman, H. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900274 · Cited by 237
Rupp, R. E., Rosenthal, S. L., & Stanberry, L. R. (2007) · PubMed · Cited by 235
Rossi, J. J., June, C. H., & Kohn, D. B. (2007) · Nature Biotechnology · doi:10.1038/nbt1367 · Cited by 231
Baert, L., van ‘t Klooster, G., Dries, W., François, M., Wouters, A., Basstanie, E., Iterbeke, K., Stappers, F., Stevens, P., Schueller, L., et al. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.03.006 · Cited by 224
Mechanism of action of licensed vaccine adjuvants
Tritto, E., Mosca, F., & De Gregorio, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.084 · Cited by 213
Dutta, T., & Jain, N. K. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.12.007 · Cited by 200
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission
Klasse, P. J., Shattock, R., & Moore, J. P. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061206.112737 · Cited by 178
Progress and obstacles in the development of an AIDS vaccine
Letvin, N. L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1959 · Cited by 176
Weber, N., Ortega, P., Clemente, M. I., Shcharbin, D., Bryszewska, M., de la Mata, F. J., Gómez, R., & Muñoz-Fernández, M. A. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.035 · Cited by 175
Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy
Hori, Y., Winans, A. M., Huang, C. C., Horrigan, E. M., & Irvine, D. J. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.05.033 · Cited by 175
Akagi, T., Wang, X., Uto, T., Baba, M., & Akashi, M. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.04.023 · Cited by 173
Vaginal Drug Delivery Systems for HIV Prevention
Rohan, L. C., & Sassi, A. B. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9082-7 · Cited by 166
Jiang, Y.-H., Emau, P., Cairns, J. S., Flanary, L., Morton, W. R., McCarthy, T. D., & Tsai, C.-C. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.207 · Cited by 160
Dutta, T., Agashe, H. B., Garg, M., Balasubramanium, P., Kabra, M., & Jain, N. K. (2007) · Journal of drug targeting · doi:10.1080/10611860600965914 · Cited by 157
The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles
Lee, A. L. Z., Wang, Y., Cheng, H. Y., Pervaiz, S., & Yang, Y. Y. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.10.062 · Cited by 157
Nanoparticle strategies for the oral delivery of insulin
Damgé, C., Reis, C. P., & Maincent, P. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.45 · Cited by 154
Gandhi, R. T., & Walker, B. D. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104011 · Cited by 143
The HIV–AIDS Pandemic at 25 — The Global Response
MERSON, M. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068074 · Cited by 141
Dutta, T., Garg, M., & Jain, N. K. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.04.002 · Cited by 140
Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles
Ham, A. S., Cost, M. R., Sassi, A. B., Dezzutti, C. S., & Rohan, L. C. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9765-2 · Cited by 136
NanoART, NeuroAIDS and CNS Drug Delivery
Nowacek, A. S., & Gendelman, H. E. (2009) · Nanomedicine · doi:10.2217/nnm.09.38 · Cited by 132
Whither or Wither Microbicides?
Grant, R. M., Hamer, D. H., Hope, T. J., Johnston, R., Lange, J. M. A., Lederman, M. M., Lieberman, J., Miller, C. J., Moore, J. P., Mosier, D. E., et al. (2008) · Science · doi:10.1126/science.1160355 · Cited by 131
Lymphatic targeting of zidovudine using surface-engineered liposomes
Kaur, C. D., Nahar, M., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802475688 · Cited by 127
Lipid based particulate formulations for the delivery of antigen
Copland, M. J., Rades, T., Davies, N. M., & Baird, M. A. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01315.x · Cited by 118
Lentiviral-mediated delivery of siRNAs for antiviral therapy
Morris, K. V., & Rossi, J. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302688 · Cited by 111
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites
Vyas, T. K., Shah, L. K., & Amiji, M. M. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.5.613 · Cited by 108
Lee, S., Dykxhoorn, D. M., Kumar, P., Ranjbar, S., Song, E., Maliszewski, L. E., François-Bongarçon, V., Goldfeld, A. E., Swamy, N. M., Lieberman, J., et al. (2005) · Blood · doi:10.1182/blood-2004-10-3959 · Cited by 105
Lamalle-Bernard, D., Munier, S., Compagnon, C., Charles, M., Kalyanaraman, V. S., Delair, T., Verrier, B., & Ataman‐Önal, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.006 · Cited by 98
Bielinska, A. U., Janczak, K. W., Landers, J. J., et al. (2008) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2007.0148 · Cited by 94
Wang, X., Uto, T., Akagi, T., Akashi, M., & Baba, M. (2007) · Journal of Medical Virology · doi:10.1002/jmv.21029 · Cited by 91
Wu, Y., Navarro, F., Lal, A., Basar, E., Pandey, R. K., Manoharan, M., Feng, Y., Lee, S. J., Lieberman, J., & Palliser, D. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.12.003 · Cited by 91
Dou, H., Morehead, J., Destache, C. J., Kingsley, J. D., Shlyakhtenko, L. S., Zhou, Y., Chaubal, M. V., Werling, J. O., Kipp, J., Rabinow, B. E., et al. (2006) · Virology · doi:10.1016/j.virol.2006.08.012 · Cited by 90
Dendritic cell‐based human immunodeficiency virus vaccine
Rinaldo, C. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02047.x · Cited by 90
Design Opportunities for Actively Targeted Nanoparticle Vaccines
Fahmy, T. M., Demento, S. L., Caplan, M. J., Mellman, I., & Saltzman, W. M. (2008) · Nanomedicine · doi:10.2217/17435889.3.3.343 · Cited by 87
Sakaue, G., Hiroi, T., Nakagawa, Y., Someya, K., Iwatani, K., Sawa, Y., Takahashi, H., Honda, M., Kunisawa, J., & Kiyono, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.495 · Cited by 79
Nanotechnology for drug delivery: the perfect partnership
Farokhzad, O. C. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.9.927 · Cited by 79
Self-citationAline, F., Brand, D., Pierre, J., Roingeard, P., Munier, S., Verrier, B., & Dimier‐Poisson, I. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.028 · Cited by 77
Li, M., & Rossi, J. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-935-4:261 · Cited by 75
Garg, M., Asthana, A., Agashe, H. B., et al. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.5.0005 · Cited by 72
Eradication of HIV: current challenges and new directions
Marsden, M. D., & Zack, J. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn455 · Cited by 68
Garg, M., Dutta, T., & Jain, N. K. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.12.019 · Cited by 64
Dorrell, L., Williams, P., Suttill, A., Brown, D., Roberts, J., Conlon, C. P., Hanke, T., & McMichael, A. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.005 · Cited by 57
Miyake, A., Akagi, T., Enose, Y., Ueno, M., Kawamura, M., Horiuchi, R., Hiraishi, K., Adachi, M., Serizawa, T., Narayan, O., et al. (2004) · Journal of Medical Virology · doi:10.1002/jmv.20100 · Cited by 55
Wang, X., Uto, T., Akagi, T., Akashi, M., & Baba, M. (2007) · Journal of Virology · doi:10.1128/jvi.00489-07 · Cited by 52
Extensive HIV-1 Intra-Host Recombination Is Common in Tissues with Abnormal Histopathology
Lamers, S. L., Salemi, M., Galligan, D. C., de Oliveira, T., Fogel, G. B., Granier, S. C., Zhao, L., Brown, J. N., Morris, A., Masliah, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005065 · Cited by 51
LI, M., Li, H., & Rossi, J. J. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.006 · Cited by 51
Guillon, C., Mayol, K., Terrat, C., Compagnon, C., Primard, C., Charles, M., Delair, T., Munier, S., & Verrier, B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.060 · Cited by 49
Wan, L., Pooyan, S., Hu, P., Leibowitz, M. J., Stein, S., & Sinko, P. J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9402-5 · Cited by 40
Wan, L., Zhang, X., Pooyan, S., Palombo, M. S., Leibowitz, M. J., Stein, S., & Sinko, P. J. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070066k · Cited by 33
Towards a durable RNAi gene therapy for HIV-AIDS
Berkhout, B., & ter Brake, O. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802653619 · Cited by 31
Fairman, J., Moore, J., Lemieux, M., Rompay, K. K. A. V., Geng, Y., Warner, J. F., & Abel, K. (2009) · Human Vaccines · doi:10.4161/hv.5.3.6589 · Cited by 28
Li, M., & Rossi, J. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_18 · Cited by 28
Kawamura, M., Wang, X., Uto, T., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20317 · Cited by 19
Barnor, J. S., Miyano‐Kurosaki, N., Yamaguchi, K., Abumi, Y., Ishikawa, K., Yamamoto, N., & Takaku, H. (2005) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-200059981 · Cited by 19
Immunotherapies in HIV-1 infection
Pett, S. L. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328329d090 · Cited by 16
Merck's HIV vaccine flop brings vectors under closer scrutiny
Ledford, H. K. (2008) · Nature Biotechnology · doi:10.1038/nbt0108-3 · Cited by 5
Patent life of antiretroviral drugs approved in the US from 1987 to 2007
Rodríguez-Monguió, R., & Seoane-Vazquez, E. C. (2009) · AIDS Care · doi:10.1080/09540120802511950 · Cited by 3
Saïdi, H. (2008) · Reviews in Medical Virology · doi:10.1002/rmv.601 · Cited by 3
Topical antiviral siRNA: A practical siRNA microbicide?
Rossi, J. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302764 · Cited by 2
Cited by
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Applications of nanoparticle systems in drug delivery technology
Rizvi, S. A. A., & Saleh, A. M. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.10.012 · Cited by 1,334
Advances in drug delivery systems, challenges and future directions
Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17488 · Cited by 1,040
Microbial lipases and their industrial applications: a comprehensive review
Chandra, P., Enespa, Singh, R., & Arora, P. K. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01428-8 · Cited by 887
Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus
Ensign, L. M., Tang, B. C., Wang, Y.-Y., Tse, T. A., Hoen, T., Cone, R., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003453 · Cited by 368
Metadata
- Authors
- Mamo, T., Moseman, E. A., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D. R., Langer, R., Andrian, U. V., & Farokhzad, O. C.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2010-02
- Volume
- 5
- Issue
- 2
- Pages
- 269-285
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2094146325
- Cited by
- 255
- References
- 118
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.